General Information |
| Summary |
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2021-07-26 |
| End date (estimated) |
2039-09-30 |
| Clinical feature |
| Label |
chronic lymphocytic leukemia |
| Link |
http://purl.obolibrary.org/obo/DOID_1040 |
| Description |
A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.; Xref MGI. |
|
Administrative Information |
| NCT number |
NCT04629729 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04629729 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT04629729 |
| Public contact |
| Email |
FateTrialDisclosure@fatetherapeutics.com |
| Public email |
FateTrialDisclosure@fatetherapeutics.comFateTrialDisclosure@fatetherapeutics.com |
| First name |
Fate Trial Disclosure |
| Last name |
Fate Trial Disclosure |
| Phone |
+1 866-875-1800 |
| Country |
|
|
| Sponsors |
Fate Therapeutics
|
Cells |
| Which differentiated cell type is used |
| Label |
T cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000084 |
| Description |
A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
396 |
